Twist Bioscience

Increase Speed to Market with Streamlined, De-Risked Antibody Development

Our unique technology enables us to print large amounts of DNA with game-changing throughput and quality. With that as our foundation, Twist Biopharma can create unprecedented synthetic antibody libraries, accelerating the way you develop antibody candidates.

End-to-End Antibody Development



Writing the Next Chapter in Antibody Therapeutics

Our DNA writing capabilities, combined with our leading bioinformatics expertise, give us the ability to offer unique benefits for lead identification and optimization. Twist’s antibody discovery platform, the “Library of Libraries,” and any custom libraries we build, are designed rationally, focused on interrogating only the desired sequence space. We can also remove frame shifts, stop codons, and potential downstream manufacturing liabilities, such as isomerization, cleavage, deamidation, glycosylation, or problematic dipeptide motifs from sequence space, empowering faster and de-risked discovery and optimization efforts.



Provides end-to-end solutions in biologic drug discovery and early development

We offer tailored services and workflows for your individual needs, across the preclinical continuum. In addition to our antibody discovery and optimization services, we offer supporting development capabilities, including IgG conversion, expression, purification, biophysical characterization, and functional characterization. And if you want to quickly tap into potent antibodies, our antibody experts have discovered and vetted a collection of antibodies against an array of high-value targets from important therapeutic areas, such as immuno-oncology, obesity and diabetes, rare metabolic diseases, and COVID-19.